Lonza ( (LZAGY) ) has released its Q2 earnings. Here is a breakdown of the information Lonza presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lonza Group Ltd, a leading global provider in the pharmaceutical and biotechnology sectors, specializes in contract development and manufacturing services, with a focus on biologics, advanced synthesis, and specialized modalities. In its latest half-year earnings report for 2025, Lonza reported robust financial performance with group sales reaching CHF 3.6 billion, marking a 19% growth at constant exchange rates. The company’s CORE EBITDA stood at CHF 1.1 billion, reflecting a margin improvement to 29.6%. The CDMO business, a significant contributor, delivered sales of CHF 3.1 billion, showcasing a 23.1% growth. Lonza’s Integrated Biologics segment experienced a remarkable 39.3% sales growth, driven by acquisitions and high demand, while Advanced Synthesis also showed strong performance with an 18.3% sales increase. However, Specialized Modalities faced a decline in sales due to pipeline variability and operational challenges. The Capsules & Health Ingredients segment remained stable, with expectations for recovery in the latter half of the year. Looking ahead, Lonza’s management remains optimistic, projecting continued growth in the CDMO segment and a steady recovery in the Capsules & Health Ingredients business, while anticipating improvements in Specialized Modalities in the second half of 2025.